The estimated Net Worth of Jonathan S. Wolin is at least $384 mil dollars as of 17 May 2024. Mr. Wolin owns over 871 units of Jaguar Health Inc stock worth over $2,274 and over the last 5 years he sold JAGX stock worth over $0. In addition, he makes $381,395 as Chief of Staff e General Counsel and Chief Compliance Officer at Jaguar Health Inc.
Jonathan has made over 6 trades of the Jaguar Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 871 units of JAGX stock worth $984 on 17 May 2024.
The largest trade he's ever made was exercising 6,666 units of Jaguar Health Inc stock on 5 April 2022 worth over $7,533. On average, Jonathan trades about 809 units every 70 days since 2020. As of 17 May 2024 he still owns at least 2,012 units of Jaguar Health Inc stock.
You can see the complete history of Mr. Wolin stock trades at the bottom of the page.
Jonathan S. Wolin serves as Chief of Staff, General Counsel and Chief Compliance Officer of the Company. Mr. Wolin served as an independent consultant advising clients on corporate compliance from June 2017 to November 2018, as Chief Administrative Officer of Braden Partners (d/b/a Pacific Pulmonary Services) from September 2016 to May 2017, as Chief Compliance Officer of Natera, Inc. from June 2015 to August 2016, and as Chief Compliance Officer of Braden Partners from September 2013 to May 2015. Mr. Wolin holds a J.D. from The Catholic University of America, Columbus School of Law, an M.B.A. from The George Washington University—School of Business and a B.S. in Accounting from the University of Maryland.
As the Chief of Staff e General Counsel and Chief Compliance Officer of Jaguar Health Inc, the total compensation of Jonathan Wolin at Jaguar Health Inc is $381,395. There are 3 executives at Jaguar Health Inc getting paid more, with Lisa Conte having the highest compensation of $1,433,160.
Jonathan Wolin is 58, he's been the Chief of Staff e General Counsel and Chief Compliance Officer of Jaguar Health Inc since 2019. There are 8 older and 5 younger executives at Jaguar Health Inc. The oldest executive at Jaguar Health Inc is James Bochnowski, 76, who is the Independent Chairman of the Board.
Jonathan's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.
Over the last 10 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski, eInvestments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Jaguar Health Inc executives and other stock owners filed with the SEC include: